MYOS Stock UPDATES Myos Corp (MYOS) 14.75 08/03/2014 14:17:5

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Myos Corp (MYOS) 14.75 $MYOS

MYOS elects Douglas Weekes as chief commercial officer
M2 - Thu Jul 31, 5:49AM CDT
Biotherapeutics company MYOS (NASDAQ:MYOS) reported on Wednesday that Douglas Weekes has been named as its chief commercial officer.

MYOS Corporation Announces Appointment of Douglas Weekes as Chief Commercial Officer
Marketwire - Wed Jul 30, 7:04AM CDT
MYOS Corporation ("MYOS" or the "Company" (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has appointed Douglas Weekes as Chief Commercial Officer. Mr. Weekes will lead the Company's marketing, sales and product development of a portfolio of commercial products derived from the first clinically proven natural myostatin inhibitor, Fortetropin(TM). Positive clinical results have demonstrated that daily use of Fortetropin along with exercise may be beneficial to improving lean muscle mass, which has significant therapeutic effects for overall health including bone density, control of serum glucose, triglyceride levels and reduced inflammation. Mr. Weekes will lead the creation of several bionutrition products including bars, meal replacement formats and ready to drink beverages utilizing Fortetropin.

MYOS renews manufacturing and supply agreement of Fortetropin with DIL
M2 - Mon Jul 28, 6:19AM CDT
Biotherapeutics company MYOS (NASDAQ:MYOS) said on Friday that it has extended its agreement for the continued manufacturing and supply of the first clinically proven natural myostatin inhibitor Fortetropin with Deutsches Institut fuer Lebensmitteltechnik e.V (DIL), the German Institute for Food Technologies.

MYOS Corporation Extends Manufacturing and Supply Agreement for Fortetropin
Marketwire - Fri Jul 25, 7:05AM CDT
MYOS Corporation ("MYOS" or the "Company" (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has signed an extension of its supply agreement with Deutsches Institut fuer Lebensmitteltechnik e.V ("DIL" , the German Institute for Food Technologies, for the continued manufacturing and supply of Fortetropin(TM), the first clinically proven natural myostatin inhibitor. DIL is a world leader in developing and providing the finest products in food technology today.

Nasdaq stocks posting largest percentage decreases
AP - Thu Jul 24, 5:23PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:

MYOS Corporation Receives Notice of Allowance of U.S. Patent Application for Proprietary Manufacturing Methods of Fortetropin
GlobeNewswire - Thu Jul 24, 7:41AM CDT
- Patent will protect MYOS' intellectual property portfolio for Fortetropin through 2033 -

MYOS Corporation Reports Positive Top-Line Clinical Study Results of Fortetropin's Muscle Building Activity in Male Subjects
Marketwire - Tue Jul 22, 7:05AM CDT
MYOS Corporation ("MYOS" or the "Company" (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today positive top-line results of its clinical trial designed to study the effects of Fortetropin(TM) (MYO-T12®) in conjunction with modest resistance training in male subjects led by Jacob Wilson, Ph.D., CSCS*D, Assistant Professor and Director of the Skeletal Muscle and Sports Nutrition Laboratory of the Department of Health Sciences and Human Performance at The University of Tampa.

MYOS Corporation Announces Agreement With Cloud Pharmaceuticals, Inc. to Develop Small Molecules Targeting Sarcopenia and Cachexia
Marketwire - Thu Jul 17, 6:05AM CDT
MYOS Corporation ("MYOS" or the "Company" (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has entered into a research and development agreement with Cloud Pharmaceuticals, Inc. The research and development program will focus on product candidates related to the inhibition of targets in the myostatin regulatory pathway as well as inflammatory mediators associated with sarcopenia and cachexia. Under the terms of the agreement MYOS will have proprietary rights to the design and structure of any small molecules developed for the muscle-health treatment market.

MYOS hires Dr. J. Craig Venter to board
M2 - Tue Jul 15, 5:06AM CDT
Biotherapeutics company MYOS (NASDAQ:MYOS) revealed on Monday the addition of genomic pioneer, Dr. J. Craig Venter, Ph.D. to its board of directors.

MYOS Corporation Appoints World Renowned Scientific Visionary and Entrepreneur, J. Craig Venter, Ph.D., to Board of Directors
Marketwire - Mon Jul 14, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company" (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has appointed genomic pioneer, J. Craig Venter, Ph.D. to its Board of Directors.

MYOS Corporation Announces Approval for Listing on the NASDAQ Capital Market
Marketwire - Wed Jul 09, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company" (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has received approval for the listing of its common stock on the NASDAQ Capital Market ("NASDAQ" . The common stock is expected to begin trading on the NASDAQ at market open on July 10, 2014 under its existing ticker symbol, MYOS. The common stock will continue to trade on the OTC Bulletin Board until market close on July 9, 2014.

MYOS Corporation Sponsors Sixth Annual Edition of Scientific American Worldview
Marketwire - Thu Jun 26, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company" (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it is a featured sponsor of the Sixth Annual Edition of Scientific American Worldview ("Worldview" .

MYOS Corporation Establishes Research Relationship With Rutgers University in Muscle Science
Marketwire - Tue Jun 24, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company" (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that the Company has entered into a three-year Master Service Agreement ("MSA" with Rutgers, The State University of New Jersey, to engage Rutgers researchers in a program which will expand the MYOS' basic science platform for further development of Fortetropin(TM), the first clinically proven natural myostatin inhibitor, and other proprietary MYOS product formulations.

MYOS' net loss from operations widens to USD4.267m in 2013
M2 - Wed Apr 02, 4:58AM CDT
Biotherapeutics company MYOS (OTCBB:MYOS)on Tuesday declared a net loss from operations of approximately USD4.267m for the full year ended 31 December 2013.

MYOS Corporation Reports 2013 Fourth Quarter and Full Year Results
Marketwire - Tue Apr 01, 6:35AM CDT
MYOS Corporation (OTCBB: MYOS)

MYOS Corporation Joins Scientific Working Group Aging in Motion to Develop Patient Centered Treatment Measures for Sarcopenia
Marketwire - Thu Mar 27, 6:35AM CDT
MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance ("MYOS" or the "Company" , announced today that it will participate in a working group on March 28, 2014 including physicians, researchers, patient groups and the U.S. Food and Drug Administration (FDA) to develop measures of clinical benefit for therapeutic products developed or used to treat sarcopenia. The group, the Aging in Motion (AIM) Coalition, was formed to promote understanding about the importance of improving research efforts and developing innovative treatments in the area of sarcopenia and age-related functional decline. At present, the FDA does not have a policy on sarcopenia and currently there are no drugs approved for this disease indication.

MYOS Corporation Takes Steps to Make a Difference in the Fight Against Muscle Disease at the New Jersey MDA Muscle Walk
Marketwire - Mon Mar 17, 7:05AM CDT
MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance ("MYOS" or the "Company" , announced today that the Company will participate in the New Jersey MDA Muscle Walk fundraising event on March 23, 2014 at the Prudential Center in Newark, NJ.

MYOS Corporation to Present Abstract on Lipidomic and Proteomic Studies of MYO-T12(R) at the International Conference on Frailty and Sarcopenia Research
Marketwire - Wed Mar 12, 7:05AM CDT
MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance ("MYOS" or the "Company" , announced today that it has been selected to present the Company's abstract entitled "Lipidomic and Proteomic Studies of Fertilized Chicken Egg Yolk: Therapeutic Implications for Sarcopenia" at the International Conference on Frailty & Sarcopenia Research (ICFSR 2014) in Barcelona, Spain, being held March 13-14, 2014.

MYOS Corporation Initiates Clinical Study of MYO-T12(R) in Adult Women
Marketwire - Thu Feb 27, 7:05AM CST
MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, today announced the initiation of its first clinical study of MYO-T12(R) in women. The study, led by Stacy Zamuido, Ph.D., Senior Scientist and Director of Research for the Department of Obstetrics and Gynecology at Hackensack University Medical Center, will determine the effect of MYO-T12(R) on blood chemistry in healthy adult females. The 20-patient clinical trial will also observe the effect of MYO-T12(R) on body mass index (BMI) and waist circumference in addition to other indices of muscle health.



Scroll down for more posts ▼

Top 10 Most Recent News Articles

LiberNovo's European Black Friday Sale Tests Demand

Updated Category News Views 110

A €1,339 chair has no business pretending it is an impulse buy, which is exactly why LiberNovo’s Black Friday push deserves a closer look. The Hong Kong-based ergonomic-chair seller has rolled out its Black Friday sale across the European Union and United Kingdom, with the campaign ending November 30 at 23:59 CET in the EU and 23:59 GMT in the UK. This is a...

Continue Reading
LNG’s Coming Glut Could Gut Global Trading Profits

Updated Category News Views 33

A five-year LNG surplus is the sort of forecast that makes people nod politely today and panic much too late. Bain & Company is putting a hard edge on that risk: the global trading profit pool could slide from an estimated $20 billion in 2026 to roughly $5.5 billion a year during a 2030–34 glut, then potentially tip below zero once cancellation costs bite. That is not a...

Continue Reading
24X Options Filing Puts Earnings Bets Before the SEC

Updated Category News Views 126

An earnings release already turns the market into a bar fight; 24X wants to put part of that fight inside a regulated binary-options contract. The Stamford-based exchange has filed a proposed rule change with the SEC for 24X Options, a facility that would offer a conventional options market alongside contracts tied to company performance targets. It is an interesting...

Continue Reading
Discount Tire’s $10 Correction Matters This Black Friday

Updated Category News Views 72

A ten-dollar correction is not a catastrophe, but it is precisely the sort of loose screw that deserves a glance before Black Friday shouting gets underway. Discount Tire says an earlier version of its Nov. 17, 2026 promotion release listed combined instant savings of $390 when the correct maximum is $380. The company issued the correction and supplied a revised release....

Continue Reading
Vizsla's Panuco Delay Puts Security Ahead of Speed

Updated Category News Views 34

A mine schedule can absorb a calendar slip; the people around a mine cannot be treated like a line item. Vizsla Silver's update on Panuco is therefore not the usual development-company chest thumping. It is a sober admission that security, permitting and site readiness have pushed first silver to the second half of 2028, one year later than the prior H2 2027 target....

Continue Reading
Automotive Laminates: Small Market, Real EV Leverage

Updated Category News Views 0

Cabin trim has become a surprisingly serious battleground, and that is the whole point of this automotive laminates story. Nobody buys a vehicle because somebody bragged about a multilayer film behind the door panel. Yet the materials under the fingertips, beneath the carpet, and around the dashboard increasingly decide whether an interior feels cheap, quiet, durable, or...

Continue Reading
Shenzhen’s APEC Moment Puts Pacific Trade Links in Focus

Updated Category News Views 80

A city that once logged eight stock trades in a day is hosting APEC with a very different kind of ledger in view. Shenzhen Stock Exchange began trial operations on December 1, 1990 with one stock, eight trades and roughly 200,000 yuan in turnover. By the end of September 2026, it had 2,908 listed companies and about 42.43 trillion yuan in combined market value. That is...

Continue Reading
American Pride Bank Tests a Fast Southeast Expansion

Updated Category News Views 154

Those old Winston-Salem smokestacks make a fitting backdrop for a bank trying to build something new, and American Pride Bank is moving with uncommon speed. Its new office at 450 N. Patterson Ave., Suite 200 sits in the Bailey South building in Innovation Quarter, across from Bailey Park and amid a district deliberately remade for founders, researchers and growing...

Continue Reading
Markley’s Lowell Campus Turns Data Land Into Arboretum

Updated Category News Views 203

Server halls rarely get credited with restoring a landscape, which is why Markley’s Lowell campus caught my eye. On November 18, 2026, the company said its Lowell data center campus had earned Level I arboretum accreditation from the ArbNet Arboretum Accreditation Program. ArbNet describes itself as the only international accreditation program specifically for arboreta,...

Continue Reading
2027 Auto Brand Awards Put Long-Term Buyer Value First Again

Updated Category News Views 32

Car shoppers staring down high prices and financing costs do not need another shiny badge; they need some help separating durable value from showroom wallpaper. That is why the 2027 U.S. News vehicle brand awards, announced Nov. 19, 2026, are worth a look. They are not a sales forecast, not a profit forecast, and certainly not a reason to blindly crown a corporate winner....

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating Trailblazers: Equity Prime Mortgage’s TAG 2025 Awards

Updated Category News Views 146

Recognizing Industry Innovators at TAG 2025 Awards spotlight collaboration, innovation, and empowerment shaping the next era of mortgage leadership. Equity Prime Mortgage (EPM), a prominent independent mortgage lender, has unveiled the winners of The American Gift (TAG) 2025 awards, honoring rising stars and leaders in the mortgage industry. During the event, founder and...

Continue Reading
GDS Holdings Set to Announce Q1 2025 Financial Performance

Updated Category News Views 144

GDS Holdings to Announce its First Quarter 2025 Financial Results GDS Holdings Limited, a prominent player in high-performance data center development and operations, is gearing up to share its financial performance for the first quarter of 2025. The announcement is expected to take place shortly before the opening of the U.S. market on May 20, 2025. As an investor and...

Continue Reading
Vineyard Workforce Insights: Skills and Opportunities Ahead

Updated Category News Views 152

Understanding the Vineyard Workforce A groundbreaking survey into the vineyard workforce has been conducted, collecting responses from nearly 1,700 workers. This survey stands as the most extensive study of its kind, yielding fascinating insights into job satisfaction, career aspirations, and the financial landscape of vineyard employees. Insight into Job Satisfaction...

Continue Reading
Explore the New Trading Opportunities with IDEX Biometrics

Updated Category News Views 126

Exciting Developments for IDEX Biometrics ASA Investors Recent efforts by IDEX Biometrics ASA have resulted in noteworthy advancements for its investors. With a strategic focus on growth and innovation, the company has successfully completed a private placement followed by a subsequent offering, significantly enhancing its financial posture. Overview of the Private...

Continue Reading
Celebrate Organic Month with Natural Grocers' Exciting Offers

Updated Category News Views 56

Celebrate Organic Month at Natural Grocers This September This September, Natural Grocers invites everyone to join in the festivities of Organic Month, featuring fantastic discounts, educational programs, and opportunities for fundraising. From September 12 to 14, customers can enjoy three days filled with amazing savings, samples, and freebies, making it the ideal time...

Continue Reading